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Abstract
Background Attention-deficit/hyperactivity disorder
(ADHD) imposes a substantial burden on patients and their
families.
Objective A retrospective, propensity score-matched
cohort study compared treatment patterns, healthcare
resource utilization (HRU) and costs among children/ado-
lescents with ADHD aged 6–17 years at treatment initia-
tion (index) in Germany who received atomoxetine (ATX)
or long-acting methylphenidate (LA-MPH) monotherapy.
Methods Patients received at least one prescription for their
index medication (ATX/LA-MPH) during 2006–2010; the
first prescriptionmarked the index date. ATX- and LA-MPH-
indexed cohorts werematched 1:1 (n = 737); a patient subset
was identified that had not received ADHD-indicated medi-
cations in 12 months prior to index (novel initiators: ATX,
n = 486; LA-MPH, n = 488). Treatment patterns were
evaluated among novel initiators, and HRU and costs among
the matched cohorts in the 12 months after index.
Results No significant differences in baseline characteristics
were found between the novel initiator patient subsets. ATX-
indexed novel initiators had significantly longer persistence
to index medication [mean (standard deviation; SD) days:
222.0 (133.9) vs 203.2 (135.0), P = 0.029) but higher
switching rates (8.8 vs 5.5 %, P = 0.045) than LA-MPH-
indexed novel initiators. The total ATX-indexed cohort
required more prescriptions [any medication; mean (SD):
20.9 (11.5) vs 15.7 (9.0), P\ 0.001] and outpatient visits
[mean (SD): 10.1 (6.3) vs 8.3 (5.3), P\ 0.001], and incurred
significantly higher total median healthcare costs (€1144 vs
€541, P\ 0.001) versus matched LA-MPH patients.
Conclusions These real-world data indicate that, among
children/adolescents with ADHD in Germany, ATX-in-
dexed patients may require more prescriptions and physi-
cian visits, and incur higher total healthcare costs, than
matched LA-MPH patients.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a
common childhood neurobehavioural disorder with core
symptoms of inattention, hyperactivity and impulsivity [1].
ADHD often persists into adolescence and adulthood, and
negatively influences academic, behavioural, emotional
and social functioning [1, 2]. Psychiatric comorbidities are
frequently present [3].
The management of ADHD in Germany involves non-
pharmacological interventions such as behavioural therapy
followed by pharmacotherapy [4]. The use of pharma-
cotherapy versus no treatment or behavioural therapy in
children and adolescents with ADHD is cost-effective from
a societal perspective [5]. Approximately one-half of the
children/adolescents diagnosed with ADHD in Germany
receive pharmacotherapy [6].
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Methylphenidate (MPH) is the pharmacotherapy most
frequently used for ADHD in Europe, and specifically in
Germany [6–8]. Various formulations of long-acting (LA)-
MPH and short-acting (SA)-MPH are available [6, 9]. SA-
MPH requires multiple daily dosing and has a number of
potential limitations, including uneven coverage through
the day, and stigmatization by peers as administration of
medication is required at school [9]. LA-MPH formula-
tions, with a maximum duration of effect of 8–12 h, are
administered once daily and, consequently, may avoid
some of the limitations of SA-MPH [9, 10].
Atomoxetine (ATX; Strattera, Lilly, Indiana, IN) is a
non-stimulant pharmacotherapy recommended for the
treatment of ADHD that has been available in Germany
since March 2005 [6]. It may be used for the treatment of
patients who respond suboptimally or are intolerant to
stimulant therapy, or have comorbidities such as tic dis-
orders [1, 11]. ATX may also be used when there are
concerns about substance misuse, or if patients express a
specific treatment preference [4, 11].
ADHD imposes a substantial economic burden on indi-
viduals, their families, and healthcare systems [12–16]. A
total direct annual cost of €3888 per patient (mean age
15 years) was reported using claims data for 2008 from a
major German health insurance fund [12]. This represents an
additional cost of €2902 versus age- and sex-adjusted con-
trols without ADHD [12]. Moreover, healthcare costs asso-
ciated with ADHD are increasing [6, 12, 16, 17]. As
estimates of ADHD prevalence have not increased over time
[18], the increasing costs are likely due to improved identi-
fication of affected patients and more intensive management
[16]. However, data on comparative treatment patterns and
associated economic burden among patients with ADHD
who receive ATX and LA-MPH in Germany are sparse [6].
This study was designed to specifically compare phar-
macotherapy treatment patterns, healthcare resource uti-
lization (HRU; including pharmacy prescriptions,
outpatient visits and inpatient admissions), and associated
costs among children and adolescents with ADHD who
received ATX or LA-MPH monotherapy.
Methods
Data
This retrospective cohort study was conducted using an
electronic medical records (EMR) database, IMS Disease
Analyzer (IMSHealth, Fairfax, VA), for Germany. The IMS
Disease Analyzer comprises longitudinal patient-level data
with more than 15 million anonymized patient records from
approximately 3000 office-based physicians inGermany; the
database is sampled using summary statistics from all
doctors in Germany as published annually by the German
Medical Association [19, 20]. The distribution of patients in
the database is similar to the overall population distribution
and provides a nationally representative and validated sam-
ple of all major German geographic regions [19].
EMR data collected from physicians in general/internal
medicine (including primary care), paediatrics, psychiatry
and neurology between 1 January 2005 and 31 December
2011 were used. Longitudinal, patient-level data were
available, including information on demographic charac-
teristics, medical diagnoses (coded using International
Classification of Diseases, Tenth Revision) and details of
prescribed medications.
Sample selection
Patients received at least one prescription forATX (Strattera)
or LA-MPH (any formulation) between 1 January 2006 and
31 December 2010 (patient selection window). The date of
the first prescription for ATX or LA-MPHmonotherapy for a
patient during this windowwas defined as the index date, and
the treatment received defined as the index medication.
Patients were 6–17 years of age at index, had available
data (including a recorded diagnosis of ADHD) from
physician visits during the 12 months prior to (baseline
period) and the 12 months after (follow-up period) the
index date, and had received at least one prescription for
their index medication during the follow-up period; they
may have received prescriptions for their index medication
in the baseline period.
Patients were excluded from the study if they had
received prescriptions for both LA-MPH and ATX at index
or within 60 days prior to index (concurrently or sequen-
tially), or had received SA-MPH at or within 60 days prior
to index; patients were not excluded for receiving any other
concomitant medications.
Patients were categorized into one of two mutually
exclusive treatment groups based on their index medica-
tion. Eligible patients who received both ATX and LA-
MPH monotherapy during the selection window were
preferentially included in the ATX-indexed group to
maximize the ATX sample size. In order to mitigate biases
from ongoing treatment users, a subset of novel initiators
(i.e. without treatment in the baseline period) was used to
evaluate treatment outcomes.
Matched treatment cohorts
Propensity score matching was used to account for
observed differences between treatment cohorts. Patients in
the ATX-indexed cohort were matched 1:1 (with a calliper
of 0.0001) to patients in the LA-MPH-indexed cohort using
a ‘nearest neighbour’ greedy matching algorithm [21].
P. Greven et al.
123
The dependent variable in the propensity score model
was the likelihood of receipt of a prescription for ATX.
The following covariates were included: age (6–12 years
or 13–17 years), sex, index year, geographical region, and
physician practice specialty at baseline; and comorbidities,
medication use, ADHD-indicated medication-naı¨vety, and
number of outpatient visits and inpatient admissions during
the 12-month baseline period. The goodness of fit of the
model was evaluated using the Hosmer–Lemeshow test and
analysis of residuals [22].
The quality of the match was assessed by graphically
comparing the overlap between the estimated propensity
score of matched and unmatched patients [22]. Generalized
linear models with negative binomial (for HRU) and
gamma (for healthcare costs) distributions were used to
verify if any residual differences in baseline variables
remained between the matched treatment cohorts.
Novel initiator subset
We identified a subset of patients from each of the matched
treatment cohorts who had not received any ADHD-indi-
cated medications (ATX, LA-MPH or SA-MPH) during the
12-month baseline period. These patients were termed
‘novel initiators’; datawere used to assess treatment patterns.
Outcome measures
Demographic and clinical characteristics recorded during the
baseline period or at index were retrieved. Treatment pat-
terns, HRU, and associated healthcare costs were evaluated.
Treatment patterns
Treatment patterns during the 12-month follow-up were
compared only in the ATX- and LA-MPH-indexed novel
initiator subsets in order to minimize the effect of ongoing
treatment. Outcomes included treatment persistence on
index medication, discontinuation, switching, restarting
and augmentation, and are defined in Table 1. Switching to
and/or augmentation with medications for psychiatric dis-
orders (antipsychotics, tranquilizers, antidepressants and
mood stabilizers, psycholeptic–psychoanaleptic combina-
tions, anticonvulsants, hypnotics/sedatives and clonidine)
were also evaluated.
HRU and total healthcare costs
Per-person HRU and the associated costs incurred by
patients with ADHD who received pharmacotherapy dur-
ing the 12-month follow-up were compared in the overall
matched ATX- and LA-MPH-indexed cohorts.
The following measures were used to evaluate HRU:
pharmacy prescriptions including ADHD-indicated medi-
cations, medications for other mental health disorders and
other (excluding ADHD and mental health-related) medi-
cations; outpatient visits to physicians in general/internal
medicine (including primary care), paediatrics, psychiatry
and neurology; inpatient admissions; and sick notes (to
excuse patients from work or school).
As the EMR database does not include cost information,
the direct medical costs were calculated from a public
reimbursement perspective by applying standardized unit
costs (for prescriptions, outpatient visits and inpatient
admissions) to quantities of per-person HRU. Unit costs
were based on standardized mean reimbursement rates
from a series of official German tariffs. Pharmacy pre-
scriptions costs were obtained from the 2011 Rote Liste
[24]. The 2011 Einheitlicher Bewertungsmaßstab (EBM;
Uniform Valuation Scheme) doctors’ fee scale was used to
calculate outpatient costs. A uniform orientation value of
€0.035 per point (attributed according to the EBM) was
Table 1 Treatment outcomes
Outcome Definition
Persistence The number of continuous days of medication from index until discontinuation, switching, augmentation or the end of the
follow-up period, whichever occurred first
Discontinuation A gap in index therapy of at least 30 days following the last day of supply of the previous prescription. The date immediately
following the 30-day gap was considered to be the discontinuation date. However, a gap of up to 90 days was permitted in
May, June and July to allow temporary suspension of medication during so-called ‘drug holidays’ [23]
Switchinga Initiation of an ADHD- or other mental health-indicated medication within 30 days after discontinuation of the index
medication. A supply of 30 days or more of the new non-index ADHD medication was required. Only the first switch was
evaluated
Restartinga Provision of a new prescription for the index medication after the switch/discontinuation date but before the end of the follow-
up period
Augmentationa Addition of a non-index medication, with at least 30 days of concurrent use with the index medication. Only the first
augmentation within the 12-month follow-up period was evaluated
ADHD attention-deficit/hyperactivity disorder
a Assessed only among patients who discontinued or switched their index medication
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assumed to derive unit costs per outpatient visit by type,
which is consistent with guidance from the German Kas-
sena¨rztliche Bundesvereinigung (National Association of
Statutory Health Insurance Physicians) [25]. Inpatient unit
costs were obtained from the 2012 German Diagnosis-
related Group catalogue; the weighted average cost was
calculated based on the diagnosis and reason for hospital-
ization [26]. For consistency, all costs were reported in
2012 German Euros using the Harmonised Index of Con-
sumer Prices [27].
Statistical analysis
Patients were grouped by index therapy and all analyses
were performed on an intent-to-treat basis. Descriptive
statistics were used to assess differences between patients
in the ATX- and LA-MPH-indexed cohorts before
propensity score matching the groups. Specifically, Pearson
Chi squared tests were used to compare categorical vari-
ables and Wilcoxon rank-sum tests were used to compare
continuous variables in the pre-match sample.
Outcome data are reported using descriptive statistics.
The duration of index medication persistence was evalu-
ated using the log-rank Chi squared test. The Chi squared
test (for categorical variables) and t test or Wilcoxon–
Mann–Whitney test (for continuous variables) were used
to assess other differences between the two groups. All
statistical tests were two-tailed at an alpha level of
P = 0.05 and choice of test type was based on data dis-




A total of 28,789 patients received at least one prescription
for ATX or LA-MPH during the patient selection window
(Fig. 1a). Of these, 4705 met all inclusion criteria and
comprised the study population (Fig. 1b). The ATX-
indexed group (n = 1174) was approximately threefold
smaller than the LA-MPH-indexed group (n = 3531).
Baseline demographic characteristics were similar in the
two groups; significant differences were observed only in
geographic region (P\ 0.001) and physician practice
specialty (P\ 0.001). Significant differences between the
two treatment cohorts were found in a number of clinical
characteristics. At index, the ATX-indexed cohort had a
higher proportion of patients who were ADHD-indicated
medication-naı¨ve (during the 12-month baseline period)
than did the LA-MPH-indexed cohort [764/1174 (65.1%)
vs 2134/3531 (60.4%), P = 0.005], but a lower proportion
of patients who were index medication-naı¨ve [1008/1174
(85.9%) vs 3143/3531 (89.0%), P = 0.004]. The ATX-
indexed cohort also had a higher proportion of patients who
were MPH medication-naı¨ve at index [896/1174 (76.3%)
vs 2140/3531 (60.6%), P\ 0.001]. Over the baseline
period, the ATX-indexed cohort received a higher mean
number of prescriptions for any medication than did the
LA-MPH-indexed cohort (8.7 vs 7.4, P\ 0.001).
Matched treatment cohorts
A total of 737 patients from the ATX-indexed cohort were
matched with the same number of patients from the LA-
MPH-indexed cohort (total n = 1474; Fig. 1b). The two
treatment cohorts matched within decile subgroups
(P = 0.652), indicating that the propensity score model
was well calibrated.
The baseline demographic and clinical characteristics
are presented in Table 2. The majority of patients in the
matched cohorts were 6–12 years of age (71.3%) and male
(80.3%). Most of the recorded outpatient visits were con-
ducted by paediatricians (61.0%) or psychiatrists (31.6%).
No significant differences between the ATX- and the
LA-MPH-indexed cohorts were found in: sex, age or the
proportion of patients at index who were index medication-
naı¨ve or any ADHD-indicated medication-naive (Table 2).
Furthermore, no significant differences were found in the
prevalence of psychiatric comorbidities or the number of
prescriptions (for any medication) received over the base-
line period. However, significant differences between the
matched cohorts remained in two baseline characteristics: a
greater proportion of ATX- than LA-MPH-indexed patients
were naı¨ve to all MPH medications (77.6 vs 66.4%,
P\ 0.001) and a greater proportion of ATX-indexed
patients received other (non-ADHD) mental health medi-
cations during the baseline period (6.2 vs 3.4%,
P = 0.011).
Multivariate regression analysis was used to adjust for
residual differences, by incorporating significant variables
[‘Naı¨ve to all MPH medications’ and ‘Received other (non-
ADHD) mental health medications during the baseline
period’] into regression models to estimate mean values for
outpatient visits and total costs as both main effects and
interaction terms. The predicted means were similar to the
original estimates.
Novel initiator subsets
A subset of patients who had not received any ADHD
medication during the baseline period was identified from
each matched cohort (Fig. 1b). These ‘novel initiator’
subsets comprised 486 ATX-indexed and 488 LA-MPH-
indexed patients.




Fig. 1 Study population. a Patient selection, SA-MPH short-acting methylphenidate. b Matched atomoxetine (ATX)- and long-acting
methylphenidate (LA-MPH)-indexed patients
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Table 2 Baseline demographic and clinical characteristics of the two matched treatment cohorts
Measure ATX LA-MPH Overall P value
n = 737 n = 737 n = 1474
Female 153 (20.8) 137 (18.6) 290 (19.7) 0.295
Age group, years 0.527
6–12 531 (72.0) 520 (70.6) 1051 (71.3)
13–17 206 (28.0) 217 (29.4) 423 (28.7)
Mean 10.9 11.2 11.1
SD 2.7 2.6 2.6
Median 11.0 11.0 11.0
Regiona 0.943
I (S–H, HAM, N–S, BRE) 177 (24.0) 166 (22.5) 343 (23.3)
II (N–W) 239 (32.4) 236 (32.0) 475 (32.2)
III (HES, SAA, R–P) 98 (13.3) 97 (13.2) 195 (13.2)
IV (B–W) 29 (3.9) 25 (3.4) 54 (3.7)
V (BAY) 101 (13.7) 107 (14.5) 208 (14.1)
VI (B) 23 (3.1) 30 (4.1) 53 (3.6)
VII (MEC, BRA, S–A) 47 (6.4) 54 (7.3) 101 (6.9)
VIII (TH, SAC) 23 (3.1) 22 (3.0) 45 (3.1)
Insurance 0.568
Member 39 (5.3) 39 (5.3) 78 (5.3)
Dependant (family member) 607 (82.4) 623 (84.5) 1230 (83.4)
Private 57 (7.7) 44 (6.0) 101 (6.9)
Retiree 34 (4.6) 31 (4.2) 65 (4.4)
Practice specialty 0.817
General/internal medicine 48 (6.5) 42 (5.7) 90 (6.1)
Paediatrics 446 (60.5) 453 (61.5) 899 (61.0)
Psychiatric 232 (31.5) 234 (31.8) 466 (31.6)
Neurology 11 (1.5) 8 (1.1) 19 (1.3)
Comorbid conditionsb
Learning difficulties 121 (16.4) 100 (13.6) 221 (15.0) 0.126
Accidental injury 81 (11.0) 88 (11.9) 169 (11.5) 0.567
Anxiety and other neurotic disorders 52 (7.1) 49 (6.6) 101 (6.9) 0.757
Conduct disorder 44 (6.0) 53 (7.2) 97 (6.6) 0.344
Emotional disorders 46 (6.2) 36 (4.9) 82 (5.6) 0.256
Naı¨ve to treatment during the 12-month baseline period
Naı¨ve to all ADHD-indicated medications—ATX, LA-MPH, SA-MPH 486 (65.9) 488 (66.2) 974 (66.1) 0.912
Naı¨ve to all MPH medications 572 (77.6) 489 (66.4) 1061 (72.0) \0.001
Naı¨ve to index ADHD-indicated medications 637 (86.4) 655 (88.9) 1292 (87.7) 0.154
Pre-index other mental health medicationsc 46 (6.2) 25 (3.4) 71 (4.8) 0.011
Data are given as n (%) unless indicated otherwise
ATX atomoxetine, LA-MPH long-acting methylphenidate, MPH methylphenidate, SA-MPH short-acting methylphenidate, SD standard deviation
a Regions were defined by A¨rztestatistik der Bundesa¨rztekammer (physicians’ statistics of the German Medical Association) [28]: B Berlin, BAY
Bayern, BRA Brandenburg, BRE Bremen, B–W Baden–Wu¨rttemberg, HAM Hamburg, HES Hessen, MEC Mecklenburg–Vorpommern, N–S
Niedersachsen, N–W Nordrhein–Westfalen, R–P Rheinland-Pfalz, S–A Sachsen–Anhalt, SAA Saarland, SAC Sachsen, S–H Schleswig–Holstein,
TH Thu¨ringen
b Five most commonly reported comorbidities are presented
c Pre-index medications among patients with at least one event
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The baseline demographic and clinical characteristics of
the two novel initiator subsets are presented in Table 3.
Similar to the matched treatment cohorts, the majority of
patients in the novel initiator subsets were 6–12 years of
age (72.8%) and male (79.6%). No significant differences
in baseline characteristics were found between the ATX-
and the LA-MPH-indexed novel initiator subsets.
Treatment patterns
All treatment pattern outcomes were evaluated in the novel
initiator subset only.
ATX-indexed novel initiators demonstrated significantly
longer persistence to their index medication than did LA-
MPH-indexed novel initiators [mean (standard deviation;
SD) number of days 222.0 (133.9) vs 203.2 (135.0),
P = 0.029]. LA-MPH-indexed novel initiators had signif-
icantly higher index medication discontinuation rates
compared with ATX-indexed novel initiators [269/486
(55.4%) vs 285/488 (58.4%), P\ 0.001]. ATX-indexed
novel initiators had significantly higher rates of switching
(to a non-index ADHD- or other mental health-indicated
medication) than did LA-MPH-indexed novel initiators
[43/486 (8.8%) vs 27/488 (5.5%), P = 0.045; Table 4].
Specifically, 3.3% (16/486) of ATX-indexed novel initia-
tors switched to LA-MPH and 0.2% (1/488) of LA-MPH-
indexed novel initiators switched to ATX. A significantly
greater proportion of LA-MPH- compared with ATX-in-
dexed novel initiators restarted their index medication after
either discontinuation or switching [171/181 (94.5%) vs
87/126 (69.0%), P\ 0.001; Table 4]. Similar rates of
augmentation (with any medication) were observed among
ATX- and LA-MPH-indexed novel initiators [83/486
(17.1%) vs 89/488 (18.2%), P = 0.635]. ATX-indexed
novel initiators were less likely to augment with SA-MPH
than were LA-MPH-indexed novel initiators [23/486
(4.7%) vs 64/488 (13.1%), P\ 0.001), but more likely to
augment with antipsychotics [37/486 (7.6%) vs 16/488
(3.3%), P = 0.003].
The majority of (first) switches/augmentations occurred
within the initial 90 days of treatment among both ATX-
and LA-MPH-indexed novel initiators (Table 4). The mean
(SD) time to first switch/augmentation of index medication
was slightly, although not significantly, longer among
ATX- than LA-MPH-indexed novel initiators [97.0 (91.7)
days vs 84.3 (79.1) days, P = 0.253].
HRU and total healthcare costs
The HRU and cost analyses reported below were evaluated
among the two matched cohorts, which included novel
initiators and ongoing treatment users (ATX, n = 737; LA-
MPH, n = 737).
Patients in the ATX-indexed cohort received signifi-
cantly more prescriptions (for any medication) than did the
matched LA-MPH-indexed cohort [mean (SD) number,
20.9 (11.5) vs 15.7 (9.0), P\ 0.001; Table 5]. ATX-
indexed patients received significantly more prescriptions
for ADHD-indicated medication than did LA-MPH-in-
dexed patients [mean (SD) number, 9.2 (5.1) vs 6.9 (4.0),
P\ 0.001]. Furthermore, ATX-indexed patients received
significantly more prescriptions for both index [8.0 (4.4) vs
6.2 (3.6), P\ 0.001] and other ADHD-indicated medica-
tions [SA-MPH; 4.8 (3.7) vs 2.6 (1.8), P\ 0.001).
Patients in the ATX-indexed cohort required signifi-
cantly more outpatient visits than did LA-MPH-indexed
patients [mean (SD) number, 10.1 (6.3) vs 8.3 (5.3),
P\ 0.001; Table 5]. The mean (SD) number of inpatient
admissions was similar in the ATX- and LA-MPH-indexed
cohorts [1.13 (0.3) and 1.12 (0.4), respectively;
P = 0.933]. Sick notes were issued for 0.8% (6/737) of
visits in both treatment cohorts.
Total per-person median healthcare costs were signifi-
cantly higher in the ATX-indexed cohort than the matched
LA-MPH-indexed cohort (€1144 ATX vs €541 LA-MPH,
P\ 0.001; Table 5). The greater costs were predominantly
because of higher median retail pharmacy expenditures
(€978 ATX vs €397 LA-MPH, P\ 0.001), which were
closely related to the cost of index medications (€862 ATX
vs €353 LA-MPH, P\ 0.001).
Discussion
This retrospective, propensity score-matched cohort study
of children and adolescents with ADHD in Germany
showed that ATX-indexed novel initiators had longer
persistence to their index medication, but were more likely
to switch medications compared with LA-MPH novel ini-
tiators. The overall ATX-indexed cohort (including novel
initiators and ongoing treatment users) required more pre-
scriptions and outpatient visits than did the matched LA-
MPH cohort. Accordingly, for the costs analysed, the
ATX-indexed cohort incurred higher healthcare costs
compared with the matched LA-MPH cohort. The observed
cost difference was largely driven by the larger per-patient
pharmacy costs of ATX.
LA-MPH-indexed novel initiators were more likely to
discontinue treatment than were ATX-indexed novel ini-
tiators, but were also more likely to restart their index
medication. As it may take up to 12 weeks for the optimal
effects of ATX to be achieved [29], patients may choose
not to take pharmacotherapy breaks. In contrast, the effects
of LA-MPH wane daily, so patients may perceive that they
can manage at least temporarily without treatment and then
restart LA-MPH when they decide or at the request of a
Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and…
123
family member/carer. Although it is not specifically
advised by German ADHD practice guidelines [4], some
clinicians sanction the requests of patients or their parents
for frequent LA-MPH treatment breaks over the weekend
or during short school holidays.
A greater proportion of ATX-indexed novel initiators
switched to LA-MPH compared with LA-MPH-indexed
novel initiators who switched to ATX (3.3% vs 0.2%). This
is to be expected because, although there are many reasons
for starting ADHD treatment with a non-stimulant
medication, patients may subsequently switch to MPH as it
is more efficacious than ATX [1, 4, 11, 30].
Similar overall rates of treatment augmentation were
observed among ATX- and LA-MPH-indexed novel ini-
tiators but the medications used for augmentation varied.
Concomitant SA-MPH was prescribed more frequently to
LA-MPH- than ATX-indexed novel initiators. This may be
expected as SA-MPH is sometimes used in clinical practice
to supplement the duration of effect of different formula-
tions of LA-MPH [9]. Augmentation with antipsychotic
Table 3 Baseline demographic
and clinical characteristics of
the two novel initiator subsets
Measure ATX LA-MPH Overall P value
n = 486 n = 488 n = 974
Female 106 (21.8) 93 (19.1) 199 (20.4) 0.287
Age group, years 0.078
6–12 366 (75.3) 343 (70.3) 709 (72.8)
13–17 120 (24.7) 145 (29.7) 265 (27.2)
Mean 10.7 11.1 10.9
SD 2.8 2.6 2.7
Median 10.0 11.0 11.0
Regiona 0.978
I (S–H, HAM, N–S, BRE) 130 (26.7) 119 (24.4) 249 (25.6)
II (N–W) 161 (33.1) 159 (32.6) 320 (32.9)
III (HES, SAA, R–P) 46 (9.5) 52 (10.7) 98 (10.1)
IV (B–W) 21 (4.3) 20 (4.1) 41 (4.2)
V (BAY) 59 (12.1) 59 (12.1) 118 (12.1)
VI (B) 23 (4.7) 26 (5.3) 49 (5.0)
VII (MEC, BRA, S–A) 33 (6.8) 37 (7.6) 70 (7.2)
VIII (TH, SAC) 13 (2.7) 16 (3.3) 29 (3.0)
Insurance 0.930
Member 24 (4.9) 24 (4.9) 48 (4.9)
Dependant (family member) 401 (82.5) 406 (83.2) 807 (82.9)
Private 40 (8.2) 35 (7.2) 75 (7.7)
Retiree 21 (4.3) 23 (4.7) 44 (4.5)
Practice specialty 0.992
General/internal medicine 30 (6.2) 30 (6.1) 60 (6.2)
Paediatrics 298 (61.3) 301 (61.7) 599 (61.5)
Psychiatric 152 (31.3) 152 (31.1) 304 (31.2)
Neurology 6 (1.2) 5 (1.0) 11 (1.1)
Comorbid conditionsb
Learning difficulties 82 (16.9) 65 (13.3) 147 (15.1) 0.122
Accidental injury 57 (11.7) 59 (12.1) 116 (11.9) 0.862
Anxiety and other neurotic disorders 42 (8.6) 38 (7.8) 80 (8.2) 0.627
Conduct disorder 33 (6.8) 35 (7.2) 68 (7.0) 0.815
Emotional disorders 32 (6.6) 30 (6.1) 62 (6.4) 0.780
Pre-index other mental health medicationsc 29 (6.0) 19 (3.9) 48 (4.9) 0.135
Data are given as n (%) unless indicated otherwise
a Regions defined as in Table 2
b Five most commonly reported comorbidities are presented
c Pre-index medications among patients with at least one event
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medications was observed more frequently with ATX- than
LA-MPH-indexed novel initiators. As in any retrospective
research, it is possible that unobserved variables could
drive differences in outcomes. For example, if ATX-
indexed novel initiators had more severe ADHD or comor-
bid symptoms that were not recorded (such as aggression)
than did LA-MPH-indexed novel initiators, this could be a
potential rationale why they received antipsychotic medi-
cations. The presence of such comorbidities could ultimately
result in higher HRU and costs. Future research should
explore whether such relationships occur.
Our findings are broadly in line with previous reports of
poor adherence and persistence to ADHD medications, and
relatively high augmentation rates [31–34]. However, to
our knowledge, this is the first large, population-based
study in Germany to directly compare the treatment pat-
terns and economic burden of ATX and LA-MPH
monotherapy. These data were derived from patients cov-
ered by various types of insurance (statutory and private
insurance, family member dependants and retirees), and
from all geographic regions of Germany. Previous retro-
spective studies of ADHD treatment in Germany were
conducted using claims data from a specific health insur-
ance plan or geographic area [6, 12, 17].
Strict inclusion and exclusion criteria were used in the
current study to ensure selection of only children/
Table 4 Treatment patterns among novel initiators




n = 486 n = 488 n = 974
Patients who had C1 switch to a non-index ADHD- or
other mental health-indicated medication during the
12-month follow-up period, n (%)
43 (8.8) 27 (5.5) 70 (7.2) 0.045
Patients who restarted index medication (after
discontinuation or switching) during the 12-month
follow-up period, n (%a)
87 (69.0) 171 (94.5) 258 (84.0) \0.001
Time from index to first switch or augmentation, n (%) n = 126 n = 116 n = 242
0–90 days 80 (63.5) 75 (64.7) 155 (64.0) 0.384
91–180 days 26 (20.6) 29 (25.0) 55 (22.7)
181–360 days 20 (15.9) 12 (10.3) 32 (13.2)
a Denominator is the total number of patients who switched or discontinued (ATX, n = 126; LA-MPH, n = 181; overall, n = 307)
Table 5 Per-patient healthcare resource use of the two matched treatment cohorts over the 12-month follow-up period
ATX LA-MPH Overall P value for the difference
between matched ATX
and LA-MPH cohorts
n = 737 n = 737 n = 1474
Mean (SD) number of prescriptions per patient
All medications 20.9 (11.5) 15.7 (9.0) 18.3 (10.7) \0.001
Index ADHD medications (ATX, LA-MPH) 8.0 (4.4) 6.2 (3.6) 7.1 (4.1) \0.001
Other ADHD-indicated medication (SA-MPH) 4.8 (3.7) 2.6 (1.8) 3.7 (3.1) \0.001
Mean (SD) number of visits per patient
All outpatient visits 10.1 (6.3) 8.3 (5.3) 9.2 (5.9) \0.001
Paediatric visits 10.3 (6.1) 8.7 (4.9) 9.5 (5.6) \0.001
Psychiatric visits 7.0 (4.3) 5.1 (3.3) 6.1 (3.9) \0.001
General/internal medicine visits 7.7 (5.6) 6.6 (4.8) 7.2 (5.2) 0.279
Neurology visits 2.3 (2.2) 2.2 (1.8) 2.2 (2.0) 0.742
Median ADHD-related healthcare costs, euros
Total cost 1144 541 779 \0.001
Prescription cost 978 397 618 \0.001
Outpatient cost 124 124 124 0.059
Inpatient cost 0 0 0 NA
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adolescents with a definite diagnosis of ADHD who had
received ATX or LA-MPH monotherapy at index. As ATX
and LA-MPH have different mechanisms of actions and
may be used in different lines of therapy [1, 35, 36], sub-
stantial efforts were made to ensure that the two cohorts
were as similar as possible in terms of available observed
variables. Rigorous methodology (propensity score
matching and multivariate modelling) was employed
throughout to ensure comparability of cohorts and mini-
mize bias, which is reflected in the large attrition observed
between the initial sample selection and the matched
treatment cohorts.
Another study strength was restriction of the treatment
pattern analysis to include only novel initiators. This subset
of patients had not received any ADHD-indicated medi-
cations (ATX, LA-MPH or SA-MPH) during the 12-month
baseline period. The use of novel initiators alone to eval-
uate treatment outcomes avoids biases that are associated
with data from ongoing treatment users (or so-called
‘prevalent users’) [37]. These biases result in difficulties in
both identifying events that occur early in the course of
therapy and controlling for potential confounding variables
[37]. However, this methodology is likely to generate
conservative estimates of treatment patterns as persistence
among novel initiators is expected to be lower than for
ongoing treatment users.
This study was designed to specifically focus on the
burden of children/adolescents with ADHD who received
ATX or LA-MPH who had been treated as outpatients,
prescribed medications and/or referred for inpatient man-
agement. As such, we cannot evaluate the costs associated
with multidisciplinary services such as psycho-education,
psychotherapy, or complex case management. These non-
pharmacological interventions are central to the mainte-
nance of effective long-term therapy and contribute sub-
stantially to overall treatment costs [4, 12]. It is likely that
many children/adolescents in this study would have
received concurrent behavioural therapy [4, 38] but we are
unable to predict whether the associated costs would differ
between the treatment cohorts.
We also acknowledge several weaknesses inherent to
our data source and methodology. The data used were
obtained from physicians in general/internal medicine,
paediatrics, psychiatry and neurology in Germany. We
believe that the vast majority of patients with ADHD
would have been managed by physicians in these spe-
cialties; however, it is possible that some patients may
have received treatment from other practitioners
[6, 7, 17]. We also assumed that the data provided by
healthcare professionals were current and complete,
although we fully acknowledge that this was an admin-
istrative database, as noted below. If incorrect diagnoses
or pharmacy codes were listed in the medical records, or
the record was incomplete, then our findings could be
inaccurate.
The data were derived from an EMR database and were
collected primarily as a clinical registry rather than as a
retrospective outcomes research tool. As such, neither
prescription fills nor medication consumption could be
verified. However, rigorous inclusion criteria were used to
ensure that only data on patients who were actively
engaged in treatment were evaluated. Patients were
required to have received at least two prescriptions for their
index medication to have been included in our study. This
methodology is likely to represent patients who consis-
tently took their medications, and is likely to lead to con-
servative estimates of treatment patterns.
We acknowledge that the preferential inclusion of
patients who received both ATX and LA-MPH during the
selection window into the ATX-indexed group may have
introduced a selection bias. Because of the methodology
used to match treatment cohorts in this analysis, it is pos-
sible that the ATX-indexed cohort may be more repre-
sentative of real-world practice, where patients have often
been exposed to multiple products, than the MPH-indexed
cohort. It must also be noted that the novel initiator patients
may not be truly ‘medication-naı¨ve’ as they could have
received ADHD medication prior to the specified 12-month
baseline period.
The discontinuation date was defined as the date
immediately following a 30-day gap in the index medica-
tion (except for summer drug holidays). Therefore, patients
may have discontinued their medication earlier than esti-
mated. However, we consider that the impact of this
potential underestimate is minimal as prescriptions in this
specific German EMR database typically provided a
60-day supply.
The current study is also subject to common limitations
of real-world data-based studies. Unobserved variables
may confound the outcomes in retrospective cohort studies.
In propensity score-matched studies, patients can be bal-
anced only by known cohort characteristics. There are also
limitations relating to the real-world data source, as the full
range of clinical symptoms of ADHD was poorly recorded
in this EMR database.
Conclusions
This retrospective, propensity score-matched cohort study
provides important real-world data on treatment patterns,
HRU and cost among children and adolescents with ADHD
who received ATX or LA-MPH in Germany. ATX-indexed
novel initiators had longer persistence but higher switching
rates than did LA-MPH-indexed novel initiators. The
ATX-indexed cohort required more prescriptions and
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physician visits, and incurred higher total healthcare costs
compared with the matched LA-MPH cohort. Thus, our
data suggest that the use of ATX for the treatment of
children/adolescents with ADHD in Germany may be
associated with greater HRU and costs versus LA-MPH.
Additional research is required to compare treatment pat-
terns, resource use and the associated economic burden of
ADHD among children/adolescents treated with ATX
versus other stimulant medications in Europe, and the
wider societal costs associated with ADHD.
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